PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kolb, H.-J. ; Schmid, C. ; Barrett, A.J.* ; Schendel, D.J.

Graft-versus-leukemia reactions in allogeneic chimeras.

Blood 103, 767-776 (2003)
Verlagsversion DOI
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
There is a strong graft-versus-leukemia (GVL) effect of allogeneic stem cell trans- plantation (SCT) due to elimination of tumor cells by alloimmune effector lym- phocytes. When leukemia relapses after allogeneic SCT, donor lymphocyte trans- fusions (DLTs) can induce sustained re- missions in some patients. This review summarizes the current status on clinical use of DLT, the basis of GVL reactions, problems associated with this therapy, and new strategies to improve DLT. Sev- eral multicenter surveys demonstrated that the GVL effect of DLT is most effec- tive in chronic myelogenous leukemia (CML), whereas it is less pronounced in acute leukemia and myeloma. Cytokine stimulation to induce differentiation of myeloid progenitor cells or to up-regulate costimulatory molecules on tumor cells may improve the efficacy of DLT. Infec- tions and graft-versus-host disease (GVHD) are major complications of DLT. Control of GVHD may be improved using suicide gene–modified T cells for DLT, allowing T-cell elimination if severe GVHD develops. Hopefully, in the future, GVL effect can be separated from GVHD through adoptive transfer of selected T cells that recognize leukemia-specific an- tigens or minor histocompatibility anti- gens, which are expressed predominantly on hematopoietic cells, thereby preclud- ing attack of normal tissues. In patients with leukemia and lymphomas with fast progression, tumor growth may outpace development of effector T cells. Here it may be preferable to select stem cell transplant donors with HLA-mismatches that allow alloreactive natural killer cells, which appear early after transplantation, to retain their cytolytic function. New ap- proaches for adoptive immune therapy of leukemia, which promise a better progno- sis for these patients, are being devel- oped.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
9.631
0.000
270
352
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Bone-Marrow-Transplantation; Stem-Cell Transplantation; Chronic Myeloid-Leukemia; Chronic Myelogenous Leukemia; Donor Leukocyte Infusions; Cytotoxic T-Lymphocytes; Minor Histocompatibility Antigens; Kir Ligand Incompatibility; Relapsed Multiple-Myeloma; Host-Disease
Sprache englisch
Veröffentlichungsjahr 2003
HGF-Berichtsjahr 0
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Zeitschrift Blood
Quellenangaben Band: 103, Heft: 3, Seiten: 767-776 Artikelnummer: , Supplement: ,
Verlag American Society of Hematology
Begutachtungsstatus Peer reviewed
Institut(e) CCG Hematopoetic Cell Transplants (IMI-KHZ)
Institute of Molecular Immunology (IMI)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-520300-001
G-501700-001
DOI 10.1182/blood-2003-02-0342
Erfassungsdatum 2003-12-31
[➜Korrektur melden]